Mark C. McKenna bought $991K of Apogee Therapeutics (APGE)
Executed Dec 12 2024, disclosed Dec 16 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 16 2024), the stock returned -20.0% (delay-adjusted); from the execution session (Dec 12 2024), -19.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Mark C. McKenna (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Apogee Therapeutics, Inc. (APGE). Across 1 priced purchase filing, the average 21-session return was -19.3% from execution and -20.0% from disclosure (delay-adjusted; derived). The largest single filing was $991K of APGE (20,000 sh across 2 lots, as filed), executed Dec 12 2024.
Healthcare · Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma,…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→